Catch offers a rewards debit card that allows users to earn cash back on purchases made directly from their bank accounts, eliminating credit card fees and debt. The platform provides automatic store credit at partner brands, enhancing customer loyalty while enabling users to save on everyday expenses.

ClearDATA provides a managed, healthcare‑focused cloud security service that combines expert consulting with its CyberHealth™ Cloud Security Posture Management platform. The solution continuously monitors multi‑cloud environments, applies real‑time threat intelligence, and automates compliance with regulations such as HIPAA, HITRUST, NIST, and GDPR, reducing breach risk and mean time to recovery. It also delivers audit‑ready reporting and cost‑optimization to help healthcare organizations maintain continuous compliance and accelerate product delivery.

IlluminOss provides a minimally invasive intramedullary fracture fixation system that delivers a light‑curable polymer via a percutaneous catheter, forming a patient‑specific implant that conforms to the medullary canal. The system includes fluoroscopic guidance, radiopaque markers, and a dedicated instrumentation kit to enable rapid fixation of fragility, periprosthetic, and oncologic long‑bone fractures and earlier patient mobilization.

Develops haptic wristbands that convert sound into over 4 billion vibration patterns, enabling users to perceive speech, manage tinnitus, and increase environmental awareness. These devices provide non-invasive solutions for moderate-to-severe hearing loss, ringing in the ears, and profound deafness, with training requiring just 10 minutes daily to interpret vibrations as auditory information.

Orionis Biosciences develops conditionally acting medicines using its A-KINE® and ALLO-GLUE™ platforms, which leverage targeted cytokine immunotherapies and allosteric molecular glues to enhance immune responses against cancer and other diseases. The company addresses the challenge of treating solid tumors by advancing its first-in-class reprogrammed interferon cytokine, ORB-011, currently in Phase 1 clinical trials.